Edwards Lifesciences Corp
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2023
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 44 |
|---|---|
| Financial Statements: | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 46 |
| For the Years Ended December 31, 2023, 2022, and 2021: | |
| Consolidated Statements of Operations | 47 |
| Consolidated Statements of Comprehensive Income | 48 |
| Consolidated Statements of Cash Flows | 49 |
| Consolidated Statements of Stockholders' Equity | 50 |
| Notes to Consolidated Financial Statements | 51 |
| All other schedules are omitted as they are not applicable or the required information is furnished in the Consolidated Financial Statements or notes thereto. | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.